Exelixis

NASDAQ: EXEL
$17.76
+$0.32 (+1.8%)
Closing price May 20, 2022
Exelixis shares were rising early Monday following the release of positive results from its late-stage trial of cabozantinib.
Exelixis Inc. (NASDAQ: EXEL) was up slightly in Tuesday’s trading session following positive results from a late stage trial. The company announced the presentation of positive data from subgroup...
On the close Tuesday, the PowerShares Dynamic exchange traded funds (ETFs) are set for a rebalance. These four stocks that are expected to have huge buying on the close Tuesday.
24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of August and added some color.
It appears that Exelixis assumed now would be the best time to dilute following its most recent successful in clinical trial and get more bang for its buck.
The most recent clinical trial results may have put Exelixis back on the map as a potential buyout.
24/7 Wall St. has taken a look at some of the major ASCO winners over the past week and how they have performed since before the ASCO news.
24/7 Wall St. has taken a look at a few of the major ASCO winners so far. Color and background information has also been added on each, as well as how shares have been moving and the consensus price...
Exelixis is seeing an outright implosion in its stock after news of its Phase 3 metastatic prostate cancer not meeting its primary endpoint.
These are the top analyst upgrades and downgrades from 24/7 Wall St. for Tuesday, September 2, 2014.
Source: ThinkstockCancer treatment developer Exelixis Inc. (NASDAQ: EXEL) is trading very heavy volume today and getting a sharp price boost following a positive result in a phase 3 pivotal trial of...
Exelixis may have a while longer before it gets to be a serious revenue stage company. Its stock was crushed on Wednesday, and the company has lost its $1 billion market cap.
The Quantitative Strategies team at Jefferies closely monitors the index changes. 24/7 Wall St. screened the Jefferies list of stocks that will see major position adds for the rebalance. Some of them...
Piper Jaffray analyst have a list of top biotech stock picks that could bring big gains for investors. The look for high-conviction near-term binary events and lower conviction catalysts with...
Source: ThinkstockBiotechnology stocks have had an extremely solid first half of the year. The analysts at Cowen Group point out that expectations are very high and many of the stocks have already...